Drugs / Ad2/MART-1v2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00010309 | Nov 2000 → ? | cutaneous melanoma | Genzyme, a Sanofi Company | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad2/MART-1v2 | “Arm I: Patients receive Ad2/MART-1v2 vaccine and Ad2/gp100v2 vaccine intradermally (ID) at the lowest dose level once every three weeks for either 6 or 15 weeks depending on assignment.” NCT00010309 ↗ |
| Modality | Vaccine | “Ad2/MART-1v2 vaccine” NCT00010309 ↗ |